Comparative Pharmacology
Head-to-head clinical analysis: BUSULFEX versus NEOSAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFEX versus NEOSAR.
BUSULFEX vs NEOSAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that cross-links DNA, leading to inhibition of DNA replication and cell death.
Alkylating agent that inhibits DNA replication and transcription by cross-linking DNA strands, leading to cell cycle arrest and apoptosis.
Busulfan 0.8 mg/kg IV every 6 hours for 4 days (total 16 doses) or 3.2 mg/kg IV once daily for 4 days, based on ideal body weight or actual body weight (whichever is lower).
Cyclophosphamide 500-1500 mg/m² IV every 2-4 weeks; oral 50-200 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range: 1.5-4.0 hours) in adults. In children, half-life is shorter (~1.4 hours). Clinically, this supports high-dose, fractionated dosing regimens (e.g., every 6 hours) to maintain therapeutic levels.
Terminal elimination half-life: 3-5 hours; prolonged in hepatic impairment (up to 12 hours).
Primarily hepatic metabolism via conjugation with glutathione, followed by renal excretion of metabolites. Less than 2% of the parent drug is excreted unchanged in urine. Fecal excretion is negligible.
Renal: 30-60% unchanged; biliary/fecal: 10-20% as metabolites.
Category C
Category C
Alkylating Agent
Alkylating Agent